We are live on
!
Find out more
SM
SG3 Management Portfolio holdings
AUM
$6.45K
1-Year Est. Return
61.81%
This Fund
S&P 500
This Quarter
Est. Return
+12.91%
1 Year Est. Return
-61.81%
3 Year Est. Return
-38.3%
5 Year Est. Return
-6.2%
10 Year Est. Return
–
AUM
$4.92B
AUM Growth
+$1.62B
(+49%)
Cap. Flow
+$714M
Cap. Flow
% of AUM
14.52%
Top 10 Holdings %
Top 10 Hldgs %
36.75%
Holding
1,419
New
468
Increased
175
Reduced
162
Closed
410
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$208M |
| 2 |
Amazon
AMZN
|
+$165M |
| 3 |
Advanced Micro Devices
AMD
|
+$86.9M |
| 4 |
XYZ
Block Inc
XYZ
|
+$33.2M |
| 5 |
Roku
ROKU
|
+$27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLRN
Acceleron Pharma
XLRN
|
+$10.3M |
| 2 |
Moderna
MRNA
|
+$9.79M |
| 3 |
JD.com
JD
|
+$6.14M |
| 4 |
AstraZeneca
AZN
|
+$5.27M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$4.32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 80.37% |
| 2 | Consumer Discretionary | 8.49% |
| 3 | Technology | 4.44% |
| 4 | Communication Services | 2.49% |
| 5 | Healthcare | 1.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
CALL
SoFi Technologies
SOFI
$21.8B
| $711K | 0.01% |
45,000
-129,700
| -74% | -$2.38M |
|
552
KraneShares California Carbon Allowance Strategy ETF
KCCA
$116M
| $706K | 0.01% |
+25,000
| New | +$676K |
|
553
Carnival Corporation Ltd
CCL
$30.6B
| $704K | 0.01% |
+35,000
| New | +$749K |
|
554
General Motors
GM
$74B
| $704K | 0.01% |
+12,000
| New | +$701K |
|
555
CALL
State Street SPDR S&P Retail ETF
XRT
$393M
| $704K | 0.01% |
7,800
| – | – |
|
|
556
PUT
State Street SPDR S&P Retail ETF
XRT
$393M
| $704K | 0.01% |
7,800
| – | – |
|
557
CALL
Spotify
SPOT
$113B
| $702K | 0.01% |
3,000
| – | – |
|
558
CALL
Johnson & Johnson
JNJ
$644B
| $701K | 0.01% |
+4,100
| New | +$671K |
|
559
Qfin Holdings
QFIN
$995M
| $688K | 0.01% |
+30,000
| New | +$667K |
|
|
560
CALL
AstraZeneca
AZN
$253B
| $687K | 0.01% |
5,900
-28,800
| -83% | -$3.39M |
|
561
PUT
Aurinia Pharmaceuticals
AUPH
$2.26B
| $686K | 0.01% |
30,000
-30,600
| -50% | -$725K |
|
562
CALL
Global X Uranium ETF
URA
$5.81B
| $685K | 0.01% |
30,000
-3,200
| -10% | -$84.4K |
|
563
Workday
WDAY
$45.3B
| $683K | 0.01% |
2,500
-3,500
| -58% | -$972K |
|
|
ONC
564
BeOne Medicines Ltd
ONC
$39.4B
| $677K | 0.01% |
2,500
-1,500
| -38% | -$506K |
|
565
Celldex Therapeutics
CLDX
$3.04B
| $676K | 0.01% |
17,500
-6,000
| -26% | -$261K |
|
566
IBM
IBM
$224B
| $668K | 0.01% |
+5,000
| New | +$627K |
|
|
567
CALL
Amazon
AMZN
$2.65T
| $667K | 0.01% |
+4,000
| New | +$685K |
|
568
Gibraltar Industries
ROCK
$1.33B
| $667K | 0.01% |
+10,000
| New | +$714K |
|
569
EOG Resources
EOG
$76B
| $666K | 0.01% |
+7,500
| New | +$674K |
|
|
ATVI
570
PUT
DELISTED
Activision Blizzard
ATVI
| $665K | 0.01% |
+10,000
| New | +$683K |
|
571
CALL
IMAX
IMAX
$2.86B
| $664K | 0.01% |
+37,200
| New | +$713K |
|
572
CALL
Arrowhead Research
ARWR
$9.29B
| $663K | 0.01% |
10,000
-20,000
| -67% | -$1.37M |
|
573
Match Group
MTCH
$10B
| $661K | 0.01% |
+5,000
| New | +$724K |
|
574
PUT
Coursera
COUR
$1.39B
| $660K | 0.01% |
+27,000
| New | +$821K |
|
575
Boyd Gaming
BYD
$5.49B
| $656K | 0.01% |
+10,000
| New | +$634K |
|
Similar funds
EAM
CAM
CCM
GPCM
MAM
BGCI
TPL
RC
SG3 Management's Q4 2021 Portfolio in Review
As of Q4 2021, SG3 Management held 1,419 positions worth $4.92B, up 49% from $3.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
SG3 Management deployed $714M of net new capital in Q4 2021, opening 468 new positions and adding to 175 existing holdings. Its largest new stake was Tesla: 619,500 shares worth $218M.
By sector, the portfolio is most concentrated in Miscellaneous at 80% of assets, down from 92% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Moderna, an estimated $9.79M trimmed.
- SG3 Management's largest Q4 2021 buy was Tesla: 619,500 shares worth $218M.
- SG3 Management added most to Amazon in Q4 2021, an estimated $165M increase.
- SG3 Management's biggest Q4 2021 reduction was Moderna, cutting an estimated $9.79M.
- SG3 Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $10.3M.
- SG3 Management's ten largest holdings make up 37% of its $4.92B portfolio in Q4 2021.
- SG3 Management opened 468 new positions and closed 410 in Q4 2021.
- SG3 Management's portfolio value rose 49% quarter-over-quarter to $4.92B.
Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.